Enlivex Therapeutics (ENLV)

• Market cap: $21M
• 1 day: -6.17%
• 5 days: -12.94%
• 1 month: -17.78%
• 3 months: -27.80%
• 6 months: -44.15%
• Year to date: -28.39%
• 1 year: -76.38%
• 5 years: -80.78%
• 10 years: -99.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Employees: 49

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

36% more call options, than puts

Call options by funds: $15K | Put options by funds: $11K

26% more funds holding

Funds holding: 19 [Q3] → 24 (+5) [Q4]

3.52% more ownership

Funds ownership: 11.99% [Q3] → 15.51% (+3.52%) [Q4]

8% less capital invested

Capital invested by funds: $4.31M [Q3] → $3.99M (-$323K) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 688% upside
• Avg. target: $10 1,026% upside
• High target: $13 1,364% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 22% 1-year accuracy 73 / 332 met price target	1,364% upside $13	Buy Maintained	3 Apr 2025
HC Wainwright & Co. Raghuram Selvaraju 30% 1-year accuracy 99 / 331 met price target	688% upside $7	Buy Maintained	24 Mar 2025